JP2017511135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511135A5 JP2017511135A5 JP2016559573A JP2016559573A JP2017511135A5 JP 2017511135 A5 JP2017511135 A5 JP 2017511135A5 JP 2016559573 A JP2016559573 A JP 2016559573A JP 2016559573 A JP2016559573 A JP 2016559573A JP 2017511135 A5 JP2017511135 A5 JP 2017511135A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- patient
- therapeutic
- proximal region
- bike
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971996P | 2014-03-28 | 2014-03-28 | |
| US61/971,996 | 2014-03-28 | ||
| PCT/US2015/022998 WO2015148926A1 (en) | 2014-03-28 | 2015-03-27 | Polypeptides, cells, and methods involving engineered cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188582A Division JP7091423B2 (ja) | 2014-03-28 | 2020-11-12 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511135A JP2017511135A (ja) | 2017-04-20 |
| JP2017511135A5 true JP2017511135A5 (enExample) | 2018-05-17 |
| JP6795399B2 JP6795399B2 (ja) | 2020-12-02 |
Family
ID=52829414
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559573A Active JP6795399B2 (ja) | 2014-03-28 | 2015-03-27 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2020188582A Active JP7091423B2 (ja) | 2014-03-28 | 2020-11-12 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2022096496A Active JP7575426B2 (ja) | 2014-03-28 | 2022-06-15 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2024182081A Pending JP2025004257A (ja) | 2014-03-28 | 2024-10-17 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020188582A Active JP7091423B2 (ja) | 2014-03-28 | 2020-11-12 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2022096496A Active JP7575426B2 (ja) | 2014-03-28 | 2022-06-15 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
| JP2024182081A Pending JP2025004257A (ja) | 2014-03-28 | 2024-10-17 | 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10464989B2 (enExample) |
| EP (2) | EP3122769B1 (enExample) |
| JP (4) | JP6795399B2 (enExample) |
| CN (2) | CN106715467B (enExample) |
| AU (3) | AU2015235852B2 (enExample) |
| CA (1) | CA2944199C (enExample) |
| ES (1) | ES2941679T3 (enExample) |
| PT (1) | PT3122769T (enExample) |
| WO (1) | WO2015148926A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3122769B1 (en) * | 2014-03-28 | 2023-02-22 | Regents of the University of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2017078807A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN108368520B (zh) * | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| EP3386522A4 (en) * | 2015-12-09 | 2019-06-19 | Nantcell, Inc. | Compositions and methods for treating HER2-positive metastatic breast cancer |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CN111569090A (zh) | 2016-01-15 | 2020-08-25 | 美国基因技术国际有限公司 | 用于活化γ-δ T细胞的方法和组合物 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| CA3048979A1 (en) * | 2016-12-30 | 2018-07-05 | Celularity Inc. | Genetically modified natural killer cells |
| WO2018232359A1 (en) | 2017-06-16 | 2018-12-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| AU2018355462B9 (en) * | 2017-10-26 | 2022-04-28 | Regents Of The University Of Minnesota | Recombinant immune cells, methods of making, and methods of use |
| KR20250048610A (ko) | 2017-12-22 | 2025-04-09 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 면역 효과기 세포 및 이의 용도 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| WO2019191495A1 (en) * | 2018-03-29 | 2019-10-03 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| SG11202105480WA (en) | 2018-12-02 | 2021-06-29 | Fate Therapeutics Inc | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| CA3146967A1 (en) | 2019-07-17 | 2021-01-21 | Fate Therapeutics, Inc. | Immune effector cell engineering and use thereof |
| US20230355759A1 (en) * | 2019-07-31 | 2023-11-09 | Celularity Inc. | Populations of natural killer cells comprising a cleavage resistant cd16 |
| WO2021113849A1 (en) * | 2019-12-05 | 2021-06-10 | Celularity Inc. | Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16 |
| MX2022015863A (es) | 2020-06-19 | 2023-03-23 | Fate Therapeutics Inc | Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia. |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| AU2022211039A1 (en) * | 2021-01-21 | 2023-08-10 | American Gene Technologies International Inc. | Engineered nk cells and methods of treating cancer |
| KR102894135B1 (ko) * | 2021-09-29 | 2025-12-04 | 카오티에스 주식회사 | 신규한 재조합 Fc 수용체 및 이를 포함하는 세포 |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| CN114774469B (zh) * | 2022-06-22 | 2022-11-08 | 南京艾尔普再生医学科技有限公司 | 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物 |
| US20260108605A1 (en) * | 2022-09-29 | 2026-04-23 | Shandong Simcere Biopharmaceutical Co., Ltd. | Engineered immune effector cell and composition and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US121788A (en) * | 1871-12-12 | Improvement in match-boxes | ||
| US6444789B1 (en) * | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| KR20070001931A (ko) | 2003-12-22 | 2007-01-04 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 면역 반응 장애의 치료 전략을 위한 진단법으로서 ｆｃ수용체 다형성의 용도 |
| PL2921500T3 (pl) * | 2004-07-10 | 2024-02-05 | The Institute For Cancer Research | Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US20070036786A1 (en) * | 2005-07-11 | 2007-02-15 | Nadine Tuaillon | Method of treating autoimmune disease using humanized anti-CD16A antibodies |
| US20080003225A1 (en) * | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| US8440811B2 (en) * | 2008-10-03 | 2013-05-14 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | DNA nanostructures that promote cell-cell interaction and use thereof |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| EP3122769B1 (en) | 2014-03-28 | 2023-02-22 | Regents of the University of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
-
2015
- 2015-03-27 EP EP15716303.1A patent/EP3122769B1/en active Active
- 2015-03-27 US US15/300,024 patent/US10464989B2/en active Active
- 2015-03-27 PT PT157163031T patent/PT3122769T/pt unknown
- 2015-03-27 ES ES15716303T patent/ES2941679T3/es active Active
- 2015-03-27 CN CN201580028172.2A patent/CN106715467B/zh active Active
- 2015-03-27 WO PCT/US2015/022998 patent/WO2015148926A1/en not_active Ceased
- 2015-03-27 EP EP22210531.4A patent/EP4227318A1/en active Pending
- 2015-03-27 AU AU2015235852A patent/AU2015235852B2/en active Active
- 2015-03-27 CN CN202110757729.3A patent/CN113699159A/zh active Pending
- 2015-03-27 CA CA2944199A patent/CA2944199C/en active Active
- 2015-03-27 JP JP2016559573A patent/JP6795399B2/ja active Active
-
2019
- 2019-09-19 US US16/575,624 patent/US12098182B2/en active Active
- 2019-10-16 AU AU2019250155A patent/AU2019250155B2/en active Active
-
2020
- 2020-11-12 JP JP2020188582A patent/JP7091423B2/ja active Active
-
2021
- 2021-04-19 US US17/233,979 patent/US11370825B2/en active Active
-
2022
- 2022-06-14 AU AU2022204134A patent/AU2022204134B2/en active Active
- 2022-06-15 JP JP2022096496A patent/JP7575426B2/ja active Active
-
2024
- 2024-08-12 US US18/800,744 patent/US20240417441A1/en active Pending
- 2024-10-17 JP JP2024182081A patent/JP2025004257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Volovat et al. | Oncolytic virotherapy: a new paradigm in cancer immunotherapy | |
| Matveeva et al. | Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency | |
| Choi et al. | From benchtop to bedside: a review of oncolytic virotherapy | |
| Ahmad et al. | Immune cell modulation of the extracellular matrix contributes to the pathogenesis of pancreatic cancer | |
| CN111658670B (zh) | 溶瘤腺病毒载体与过继t细胞治疗组合物及其用途 | |
| JP2017513502A5 (enExample) | ||
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| JP2016503655A5 (enExample) | ||
| JP2019519215A5 (enExample) | ||
| JP2018535668A5 (enExample) | ||
| CN107354156A (zh) | 一种敲除野生型T细胞TCR beta链的gRNA及方法 | |
| JP2016513115A5 (enExample) | ||
| JP2013544077A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| Kia et al. | Molecular characterization of a rabies virus isolated from trade dogs in Plateau State, Nigeria | |
| Calton et al. | Oncolytic viruses for multiple myeloma therapy | |
| JP2015524413A5 (enExample) | ||
| Zhao et al. | Viral pathogenesis, recombinant vaccines, and oncolytic virotherapy: applications of the canine distemper virus reverse genetics system | |
| JP2021525549A5 (enExample) | ||
| JP2018023397A5 (enExample) | ||
| JP2005523681A5 (enExample) | ||
| WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
| Pedrera et al. | Characterization of the protective cellular immune response in pigs immunized intradermally with the live attenuated African swine fever virus (ASFV) Lv17/WB/Rie1 | |
| Yang et al. | Progress in African swine fever vector vaccine development | |
| Lapp et al. | Viral oncolysis—can insights from measles be transferred to canine distemper virus? |